Clinical characteristics and incidence of pachychoriod disease

• Research type

  Research Study

• Full title

  What are the clinical characteristics and incidence of patients with pachychoroid disease in patients with age related neovascular degeneration?

• IRAS ID

  351544

• Contact name

  Adelehin Ijasan

• Contact email

  adelehin.ijasan@nhs.scot

• Sponsor organisation

  University of Edinburgh

• Clinicaltrials.gov Identifier

  Z6426984, Edinburgh university

• Duration of Study in the UK

  0 years, 5 months, 30 days

• Research summary

  This study will be used to investigate a relatively new ophthalmic disease called pachychoroid disease. It was first recognised in 2013. It affects the back of the eye and has similar presentations to another eye disease called neovascular age related macular degeneration (nAMD) which is also a disease that affects the back of the eye.

  nAMD is a sight threating disease that needs prompt treatment with expensive eye injections to help the patient to maintain their sight, if no treatment is given the patient will loose their eyesight. However pachychoroid disease can be seen less urgently.
  As there are similarities between clinical presentations of nAMD and pachychoroid disease there are some discrepancies on how we should treat pachychoroid patients in our department between clinicians. This can result in treatment of these patients challenging.

  For our study we would like to look at data from 30 patients from April 2022 - April 2024 that have already attended NHS Grampian (no new patients will be recruited) that have been diagnosed with pachychoroid disease. We would like to look at the patients bio data including their clinical presentations. We would like to be able to identify if there any identifiable characteristics between these patients and see how these patients have been treated. We would look at patients bio data and observe the clinical appearance at the back of the eye by assessing scans that are only available on our local database in NHS Grampian, we would compare all the bio data to see if there is any difference between clinical presentations and if the patient has received treatment or no treatment, which would aid us in future treatment plans in NHS Grampian.

  All data will be pseudonymised data. I have also applied for caldicott approval in NHS Grampian to access existing routine data.

• REC name

  West of Scotland REC 5

• REC reference

  24/WS/0173

• Date of REC Opinion

  12 Dec 2024

• REC opinion

  Favourable Opinion